FILTER

FILTERED INTERVIEW RESULTS

Mining
Cote d’Ivoire
Senegal
MACIG

Mouhammed Kebe

PARTNER, GENI AND KEBE
MACIG 2022
Gene and Kebe comment on how West Africa is evolving to better welcome investments.
Mining
Cote d’Ivoire
Senegal
Burkina Faso
MACIG

Sébastien de Montessus

PRESIDENT & CEO, ENDEAVOUR MINING
MACIG West Africa 2020-2021
Endeavour Mining explains its production and exploration activities as the largest gold producer in West Africa.
Mining
Mali
Senegal
MACIG

Stuart Gale

CEO, RESOLUTE MINING
MACIG West Africa 2020-2021
Resolute Mining describes progress at its Syama gold mine in Mali and at the Mako gold mine in Senegal.
Mining
Senegal
MACIG

Hicham Aziz

COUNTRY MANAGER, SENEGAL, SAUDEQUIP (JA DELMAS)
Saudequip is developing its Caterpillar dealership in parallel with Senegal’s fast-growing mining industry.
Mining
Senegal
Niger
MACIG

Liam Morrissey

CEO, MS RISK
MS Risk speaks of the danger that the war in the Sahel represents to mines and businesses.
Mining
Canada
Cote d’Ivoire
Senegal
MACIG

Richard Young

PRESIDENT AND CEO, TERANGA GOLD CORPORATION
Teranga updates GBR on its gold projects in West Africa.
Mining
Senegal
Cameroon
MACIG

Tim Livesey

CEO, ORIOLE RESOURCES
Oriole Resources explains its ambitions exploring for gold in Cameroon and Senegal.
Mining
South Africa
Senegal
Ghana
Togo
MACIG

Stéphane Cervellera

WESTERN AFRICA MANAGER, TITANOBEL
Titanobel explains its plans to expand its explosive business around the world.
Mining
Guinea
Cote d’Ivoire
Mali
Senegal
Ghana
Burkina Faso
MACIG

Martin van Gemert

MANAGING DIRECTOR, MINCON WEST AFRICA
Mincon comments on its business with the mining sector in West Africa.
Mining
Senegal
MACIG

Mike Brown

CEO, CHESSER RESOURCES
Chesser Resources is upbeat about its Diamba Sud gold resource in Eastern Senegal.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
MORE PREVIOUSLY PUBLISHED

PARTNER EVENTS

SEE ALL